[{"id":"298b3e73-8efc-4e73-b46a-0f8a07bcd548","acronym":"EMBER-3","url":"https://clinicaltrials.gov/study/NCT04975308","created_at":"2021-07-23T13:52:36.804Z","updated_at":"2025-02-25T16:16:28.798Z","phase":"Phase 3","brief_title":"A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer","source_id_and_acronym":"NCT04975308 - EMBER-3","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • exemestane • Inluriyo (imlunestrant)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 866","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 06/24/2024","primary_completion_date":" 06/24/2024","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-01-24"},{"id":"9269d88a-71af-4eec-a570-d307ba265a41","acronym":"","url":"https://clinicaltrials.gov/study/NCT05509790","created_at":"2022-08-22T13:04:12.367Z","updated_at":"2025-02-25T16:18:04.362Z","phase":"Phase 1","brief_title":"A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer","source_id_and_acronym":"NCT05509790","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inluriyo (imlunestrant)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 10/09/2022","start_date":" 10/09/2022","primary_txt":" Primary completion: 02/18/2024","primary_completion_date":" 02/18/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-01-24"},{"id":"c86caf36-50f7-4e83-bb56-4d558b8c9be3","acronym":"EMBER","url":"https://clinicaltrials.gov/study/NCT04188548","created_at":"2021-01-18T20:25:02.359Z","updated_at":"2025-02-25T13:53:03.697Z","phase":"Phase 1","brief_title":"A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer","source_id_and_acronym":"NCT04188548 - EMBER","lead_sponsor":"Eli Lilly and Company","biomarkers":" ER","pipe":" | ","alterations":" HER-2 negative • EGFR positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • everolimus • Perjeta (pertuzumab) • Piqray (alpelisib) • Verzenio (abemaciclib) • exemestane • Inluriyo (imlunestrant)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 12/10/2019","start_date":" 12/10/2019","primary_txt":" Primary completion: 06/29/2020","primary_completion_date":" 06/29/2020","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-01-22"},{"id":"cbfdb786-2bdb-4bd6-ab84-5ea52effef85","acronym":"EMBER-4","url":"https://clinicaltrials.gov/study/NCT05514054","created_at":"2022-08-24T21:07:46.773Z","updated_at":"2025-02-25T16:18:06.124Z","phase":"Phase 3","brief_title":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","source_id_and_acronym":"NCT05514054 - EMBER-4","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • letrozole • anastrozole • exemestane • Inluriyo (imlunestrant)"],"overall_status":"Recruiting","enrollment":" Enrollment 6000","initiation":"Initiation: 10/04/2022","start_date":" 10/04/2022","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 03/01/2032","study_completion_date":" 03/01/2032","last_update_posted":"2025-01-22"},{"id":"4bef796b-b171-4b4a-a80a-d9b7dc98b70c","acronym":"PIKASSO-01","url":"https://clinicaltrials.gov/study/NCT05307705","created_at":"2022-04-01T20:54:05.809Z","updated_at":"2025-02-25T16:17:30.808Z","phase":"Phase 1","brief_title":"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors","source_id_and_acronym":"NCT05307705 - PIKASSO-01","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • Inluriyo (imlunestrant) • LOXO-783"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 193","initiation":"Initiation: 05/11/2022","start_date":" 05/11/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-10-26"},{"id":"a99cbdd8-ab32-4e1c-bcc0-f2584d09e062","acronym":"EMBER-2","url":"https://clinicaltrials.gov/study/NCT04647487","created_at":"2021-01-19T20:39:53.693Z","updated_at":"2025-02-25T16:16:01.745Z","phase":"Phase 1","brief_title":"A Study of LY3484356 in Women With Breast Cancer Before Having Surgery","source_id_and_acronym":"NCT04647487 - EMBER-2","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inluriyo (imlunestrant)"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 04/21/2021","start_date":" 04/21/2021","primary_txt":" Primary completion: 11/11/2022","primary_completion_date":" 11/11/2022","study_txt":" Completion: 11/11/2022","study_completion_date":" 11/11/2022","last_update_posted":"2023-03-31"}]